Feeling sick with flu-like or COVID-19 symptoms?
Recently developed symptoms such as cough, sore throat, stuffy or runny nose, muscle or body aches, headache, fever, or loss of taste/smell.
Join to our clinical trials under the supervision of Dr. Robert Redfield, MD, PhD.
Your “Journey Step by Step”
Check your location in:
Australia
Site name: Novatrails
Site Physical Address: Level 3 Suite 301, 99 Pacific Highway, Charlestown NSW 2290
Site contact: info@novatrials.com.au
Site name: Momentum Clinical
Site Physical Address: Suite 302 32 Morrow Street, Taringa QLD
Site contact: ХХХХ
Site name: Key Health
Site Physical Address: 281 Elizabeth Street, Sydney, NSW 2000
Site contact: ХХХХ
Taiwan
Site name: Novatrails
Site Physical Address: Level 3 Suite 301, 99 Pacific Highway, Charlestown NSW 2290
Site contact: info@novatrials.com.au
Site name: Momentum Clinical
Site Physical Address: Suite 302 32 Morrow Street, Taringa QLD
Site contact: ХХХХ
Site name: Key Health
Site Physical Address: 281 Elizabeth Street, Sydney, NSW 2000
Site contact: ХХХХ
South Korea
Site name: Novatrails
Site Physical Address: Level 3 Suite 301, 99 Pacific Highway, Charlestown NSW 2290
Site contact: info@novatrials.com.au
Site name: Momentum Clinical
Site Physical Address: Suite 302 32 Morrow Street, Taringa QLD
Site contact: ХХХХ
Site name: Key Health
Site Physical Address: 281 Elizabeth Street, Sydney, NSW 2000
Site contact: ХХХХ
Uzbekistan
Site name: Novatrails
Site Physical Address: Level 3 Suite 301, 99 Pacific Highway, Charlestown NSW 2290
Site contact: info@novatrials.com.au
Site name: Momentum Clinical
Site Physical Address: Suite 302 32 Morrow Street, Taringa QLD
Site contact: ХХХХ
Site name: Key Health
Site Physical Address: 281 Elizabeth Street, Sydney, NSW 2000
Site contact: ХХХХ
How It Works
From Eligibility to Compensation
2
On-line/of-line Screening
Free health check.
A doctor will meet with you (online or in person) to make sure the study is safe for you. Check full list of criteria according to protocol. You’ll have a quick health check and free COVID/flu testing — all at no cost.
3
Treatment period
You receive study medication.
- What is it: Originator investigational product – Ratutrelvir
- Duration of the treatment: 10 days
- Previous clinical results: Preclinical studies and Phase I clinical trial in healthy volunteer
Or - Code name: Paxlovid (Nirmatrelvir- Ritonavir)
- Duration of the treatment: 5 days
4
Scheduler
Short visits.
- Screening period: up to 48 hours
- Treatment duration: 5–10 days
- Total participation: no more than 30 calendar days
- 7 study visits – may include online or on-site visits
- Optional blood sampling
5
Compensation
You receive your reward.
- Reimbursement for your time and expenses
You’ll receive compensation to cover meals, parking, and related costs during your participation.
Safety and Your Rights
You’re always in control
You can leave the study at any time — no questions asked.
Ethically approved
Every study follows international ethics standards.
Your privacy matters
All data protected under local laws.
Clinically tested
Tested in 56 healthy volunteers under medical supervision in Phase 1.
Who We Are?
“Our team of certified doctors and research specialists ensures your comfort and safety during every visit.”
Sponsor: Trawsfynydd Therapeutics AU Pty Ltd (on behalf of Traws Pharma, Inc)
Representative person form Sponsor team — Dr. Robert Redfield, MD, PhD
Ethics: Bellberry Limited, TGA, TFDA, MFDS
Australia sites:
Novatrials
Momentum Clinical Research
Key Health CBD South
Are you a doctor?
Become a participant in the referral program.
This open-label, randomized Phase IIa clinical study evaluates the safety, efficacy, and pharmacokinetics of investigational drug 83-0060 compared with standard therapy (Nirmatrelvir-Ritonavir / Paxlovid) in non-hospitalized adults with mild to moderate COVID-19.
The conditions are simple:
- Let us know that you’d like to take part in the program.
- We’ll provide information about active study sites in your area and share direct contact numbers for easy coordination.
- Refer a patient who meets the study eligibility criteria.
- The participant must sign the informed consent form and confirm a positive COVID-19 result using a RAT or PCR test at the site.
- Once the participant’s enrollment is confirmed — you’ll receive 300 AUD directly to your account.
Why it’s worth it:
- Simple and transparent payment process
- Minimal effort on your part
- An opportunity to help patients take part in an important study
Application
Schedule Your Appointment Online Today
Medheal makes it easy to book your appointments online. Choose a convenient time and get the care you need without the wait. Your health is our priority.
- Multicenter Phase IIa Trial
- Novel Mpro Antiviral
- Well-Tolerated & Safe
About the Study
Protocol 83-0060-0002
- Name – A Multicenter, Open-Label, Randomized Phase 2a study to evaluate Safety and Efficacy of 83-0060 and Standard of Care in Non-hospitalized Symptomatic Adult Participants with Mild to Moderate COVID-19
- Clinical trials status: Active
- Enrollment status: Screening
- Phase: 2a
- Geography: Australia, Taiwan, South Korea, Uzbekistan
- Sponsor: Trawsfynydd AU Pty Ltd, Australia
- Representative person form Sponsor team — Dr. Robert Redfield, MD, PhD
What is investigational product
- What is it: Originator investigational product
- Code name: 83-0060
- INN: Ratutrelvir
- Type: Original low–molecular-weight compound — covalent inhibitor of the SARS-CoV-2 main protease (Mpro, 3CLpro)
- Dosage form: Capsules containing 100 mg of active ingredient filled with white powder
- Previous clinical results: Preclinical studies and Phase I clinical trial in healthy volunteer
Who Can Participate
Find Out If You’re Eligible to Join
Who Can Take Part
- Adults aged 18 years or older inclusive at the time of signing the informed consent form.
- Positive PCR test on Covid -19 within the past 5 days after symptoms appears
- Willing to faithfully participate in this clinical trial
Who Cannot Join the Study
- Hospitalized
- Severe liver or kidney problems
- Active viral or systemic infections
- Taking medicines that interact with Paxlovid
What to Expect
*Overall duration: ~4 weeks
Study Participation Overview
- Screening period: up to 48 hours
- Treatment duration: 5–10 days
- Total participation: no more than 30 calendar days
- 7 study visits – may include online or on-site visits
- Optional blood sampling
- Regular phone check-ins for safety and follow-up
Benefits & Safety for subjects
- You’ll be under professional medical care
Our doctors and study team will monitor your health at every step — safely and with care. - Free tests and study medication
You’ll receive all study-related medical care, lab tests, and treatment at no cost. - Faster recovery — and helping others
You can access a new COVID-19 therapy early and contribute to developing better treatments for everyone. - Your choice matters
Joining is completely voluntary — you can leave the study at any time, for any reason. - Reimbursement for your time and expenses
You’ll receive compensation (~100 AUD) to cover meals, parking, and related costs during your participation.
Study Locations.